Seaport Therapeutics has dosed the first patient in its phase 2b BUOY-1 trial of GlyphAllo, a novel oral prodrug of ...

One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, ...

North East and North Cumbria NHS has begun a year-long rollout of the Healthinote digital health platform to support patients ...

Proximie has announced a new partnership with HistoSonics to support the rollout of the Edison Histotripsy System across ...

Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...

The MHRA has approved sebetralstat (Ekterly) as the first oral, on-demand treatment for hereditary angioedema (HAE) attacks ...

Pierre Fabre Laboratories have received marketing authorisation in China for BRAFTOVI (encorafenib) in combination with ...

Researchers at Imperial College London have discovered that an unusual DNA structure could be key to reversing chemotherapy ...

BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating that its phage cocktail BX004 ...

PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial evaluating PST-611, ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

Biotech company VarmX has received clearance from the US FDA to begin a phase 3 trial of its lead candidate, VMX-C001, in ...